ArticlemSphere2021
Predicting COVID-19 Severity with a Specific Nucleocapsid Antibody plus Disease Risk Factor Score.
Abstract read
In one paragraph
Article in mSphere, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- The role of SARS-CoV-2 nucleocapsid protein in antiviral immunity and vaccine development.Emerging microbes & infections · 2023Article
- Enhancement of IL-6 Production Induced by SARS-CoV-2 Nucleocapsid Protein and Bangladeshi COVID-19 Patients' Sera.Viruses · 2023Article
- The quantity and quality of anti-SARS-CoV-2 antibodies show contrariwise association with COVID-19 severity: lessons learned from IgG avidity.Medical microbiology and immunology · 2023Article
- SARS-CoV-2 Related Antibody-Dependent Enhancement Phenomena In Vitro and In Vivo.Microorganisms · 2023Review
- Exploring the Immunodominant Epitopes of SARS-CoV-2 Nucleocapsid Protein as Exposure Biomarker.Cureus · 2023Article
- Distinct anti-NP, anti-RBD and anti-Spike antibody profiles discriminate death from survival in COVID-19.Frontiers in immunology · 2023Article
- SARS-CoV-2 antibody profile of naturally infected and vaccinated individuals detected using qualitative, semi-quantitative and multiplex immunoassays.Diagnostic microbiology and infectious disease · 2022Article
- Review
- Role of Technology in Detection of COVID-19.Cureus · 2022Review
- Under-5-Minute Immunoblot Assays by Vortex Fluidic Device Acceleration.Angewandte Chemie (International ed. in English) · 2022Article
- Receptor-binding domain-based immunoassays for serosurveillance differentiate efficiently between SARS-CoV2-exposed and non-exposed farmed mink.Journal of veterinary diagnostic investigation : official publication of the American Association of Veterinary Laboratory Diagnosticians, Inc · 2022Article
- Formation and Expansion of Memory B Cells against Coronavirus in Acutely Infected COVID-19 Individuals.Pathogens (Basel, Switzerland) · 2022Article
- Article
- Atypical Antibody Dynamics During Human Coronavirus HKU1 Infections.Frontiers in microbiology · 2022Article
- Association between IgG responses against the nucleocapsid proteins of alphacoronaviruses and COVID-19 severity.Frontiers in immunology · 2022Article
- Distinct SARS-CoV-2 antibody reactivity patterns elicited by natural infection and mRNA vaccination.NPJ vaccines · 2021Article
- Review
- Predicting COVID-19 Severity with a Specific Nucleocapsid Antibody plus Disease Risk Factor Score.mSphere · 2021Article
- Advances in understanding the formation and fate of B-cell memory in response to immunization or infection.Oxford open immunology · 2021Review
Corrections and comments
- Update of
Authors and funding
19 authors.
Sanjana R Sen *Department of Molecular Biology & Biochemistry, University of California Irvine, Irvine, California, USA.ORCID 0000-0002-1535-814X
Emily C Sanders *Department of Chemistry, University of California Irvine, Irvine, California, USA.ORCID 0000-0003-1043-5772
Kristin N Gabriel *Department of Molecular Biology & Biochemistry, University of California Irvine, Irvine, California, USA.ORCID 0000-0002-9518-0483
Brian M MillerDepartment of Chemistry, University of California Irvine, Irvine, California, USA.ORCID 0000-0001-9186-3706
Hariny M IsodaDepartment of Chemistry, University of California Irvine, Irvine, California, USA.ORCID 0000-0003-0724-0667
Gabriela S SalcedoDepartment of Chemistry, University of California Irvine, Irvine, California, USA.ORCID 0000-0002-9794-3894
Jason E GarridoDepartment of Molecular Biology & Biochemistry, University of California Irvine, Irvine, California, USA.ORCID 0000-0003-0741-8672
Rebekah P DyerDepartment of Molecular Biology & Biochemistry, University of California Irvine, Irvine, California, USA.ORCID 0000-0001-5407-3561
Rie NakajimaDepartment of Physiology and Biophysics, University of California Irvine, Irvine, California, USA.ORCID 0000-0002-6026-3342
Aarti JainDepartment of Physiology and Biophysics, University of California Irvine, Irvine, California, USA.ORCID 0000-0002-9536-0097
Ana-Maria CaldaruseDepartment of Pharmaceutical Sciences, University of California Irvine, Irvine, California, USA.ORCID 0000-0002-8239-5637
Alicia M SantosDepartment of Chemistry, University of California Irvine, Irvine, California, USA.ORCID 0000-0002-0887-2140
Keertna BhuvanDepartment of Chemistry, University of California Irvine, Irvine, California, USA.ORCID 0000-0001-8760-2570
Delia F TifreaDepartment of Pathology and Laboratory Medicine, University of California Irvine, Irvine, California, USA.ORCID 0000-0002-7531-9337
Joni L Ricks-OddieCenter for Statistical Consulting, Department of Statistics, University of California Irvine, Irvine, California, USA.ORCID 0000-0002-9305-7692
Philip L FelgnerDepartment of Physiology and Biophysics, University of California Irvine, Irvine, California, USA.ORCID 0000-0002-4117-8505
Robert A EdwardsDepartment of Pathology and Laboratory Medicine, University of California Irvine, Irvine, California, USA.ORCID 0000-0001-9145-382X
Sudipta MajumdarDepartment of Chemistry, University of California Irvine, Irvine, California, USA.ORCID 0000-0001-6738-2267
Gregory A WeissDepartment of Molecular Biology & Biochemistry, University of California Irvine, Irvine, California, USA gweiss@uci.edu.ORCID 0000-0003-0296-9846
Funding
Univ.of Calif., Irvine Cancer Center Support GrantP30CA062203 · NCI · UNIVERSITY OF CALIFORNIA-IRVINE · PI Melanie Funes · 1994 to 2026
$57.9MUniversity of California Health Participation in the National COVID Cohort Collaborative (N3C)UL1TR001414 · NCATS · UNIVERSITY OF CALIFORNIA-IRVINE · PI COOPER, DAN M, VILAIN, ERIC J. · 2015 to 2023
$35.1MMARC U*STAR at the University of California, IrvineT34GM069337 · NIGMS · UNIVERSITY OF CALIFORNIA-IRVINE · PI BUCHMEIER, MICHAEL JOSEPH, DE LA CRUZ, MARLENE · 2005 to 2019
$8.2MNCATS NIH HHS UL1 TR001414NCI NIH HHS P30 CA062203NIGMS NIH HHS T34 GM069337
Abstract
Effective methods for predicting COVID-19 disease trajectories are urgently needed. Here, enzyme-linked immunosorbent assay (ELISA) and coronavirus antigen microarray (COVAM) analysis mapped antibody epitopes in the plasma of COVID-19 patients (
Indexed as
Severity of Illness IndexAntibodies, ViralCell Surface Display TechniquesCoronavirus Nucleocapsid ProteinsCOVID-19Enzyme-Linked Immunosorbent AssayEpitopesHumansNucleocapsidPhosphoproteinsPrognosisRisk FactorsSARS-CoV-2Antibodies, ViralCoronavirus Nucleocapsid ProteinsEpitopesnucleocapsid phosphoprotein, SARS-CoV-2Phosphoproteinscoronavirusesepitope mappingphage displayprognosticSARS-CoV-2
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.